Commercial Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies Pharmaceutical TechnologyNovartis' Q1 was hit by generics erosion, though its Avidity-bolstered pipeline is set for a robust future.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Novartis’ Q1 was hit by generics erosion, though its Avidity-bolstered pipeline is set for a robust future. Read full story Post navigation Previous: Arcera and Fosun sign MoU for neuroscience innovationNext: The strategic investments expanding CDMO capabilities for HPAPIs and ADCs Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
